Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Brainstorm Cell buy WatchMen

Start price
€0.19
13.12.23 / 50%
Target price
-
13.12.24
Performance (%)
89.19%
Price
€0.35
03.05.24
Summary
This prediction is currently active. The BUY prediction by WatchMen for Brainstorm Cell has seen massive gains of 89.19%. This prediction currently runs until 13.12.24. The prediction end date can be changed by WatchMen at any time. WatchMen has 50% into this prediction

Brainstorm Cell Therapeutics Inc. (Symbol: BCLI) is a biotechnology company specializing in the development of innovative adult stem cell therapies for central nervous system (CNS) diseases and disorders. Headquartered in New York, the company is dedicated to leveraging its proprietary NurOwn platform, which uses autologous, patient-derived cells to treat neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). By enhancing the cells' ability to secrete neurotrophic factors (NTFs) that support nerve cells' growth, survival, and function, Brainstorm Cell is at the forefront of clinical research to address the unmet need for therapies in this rapidly evolving field. As a publicly traded company, BCLI is listed on the Nasdaq stock exchange, offering prospective investors a unique opportunity to invest in a pioneering biotech company aiming to transform the lives of millions living with neurodegenerative diseases.

Performance without dividends (%)
Name 1w 1m
Brainstorm Cell -29.507% -29.507%
iShares Core DAX® -0.922% -1.993%
iShares Nasdaq 100 0.371% -0.868%
iShares Nikkei 225® 2.224% -5.187%
iShares S&P 500 -0.026% -0.918%

Comments by WatchMen for this prediction

In the thread Brainstorm Cell diskutieren
Prediction Buy
Perf. (%) 89.19%
Target price 6.000
Change
Ends at

Buy mit Kursziel 6,0

Prediction Buy
Perf. (%) 89.19%
Target price 3.000
Change
Ends at 13.12.24

Kursziel geändert auf 3,0

Prediction Buy
Perf. (%) 89.19%
Target price
Change
Ends at 13.12.24

Kursziel geändert auf 0,0